OXiGENE (OXGN) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
OXiGENE Reports First Quarter 2016 Financial Results
May 9, 2016 8:02 AM EDTSOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today reported financial results for the first quarter of 2016.
For the three months ended March 31, 2016, OXiGENE reported a net loss of $3.3 million compared to a net loss of $2.8 million for the three months ended March 31, 2015. R&D expenses increased to $2.0 million in the first quarter of 2016 compared to $1.7 million in the first quarter of 2015, while general and administrative expenses increased to $1.4 million in the first... More
